Switching from Wegovy to Zepbound: Dosing Crossover Guide

Last Updated: March 2026

In the SURMOUNT-1 trial, tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks compared to 3.1% for placebo (NEJM, 2022). That’s 6 percentage points higher than semaglutide’s 14.9% reduction in STEP 1 (NEJM, 2021). Insurance changes, formulary exclusions, and plateau effects drive thousands of patients to switch from Wegovy (semaglutide) to Zepbound (tirzepatide) each month. The transition isn’t a simple dose swap. Tirzepatide’s dual GIP/GLP-1 mechanism requires a distinct titration protocol, even for patients already stable on high-dose semaglutide.

Why Patients Switch

CVS Health’s 2025 formulary changes removed Zepbound from preferred coverage tiers, pushing some members toward Wegovy. Other insurers made the opposite move. The result: forced medication switches based on pharmacy benefit design rather than clinical response.

Beyond insurance, clinical reasons include:

• Weight loss plateau on Wegovy: 32% of STEP 1 participants regained weight between weeks 60-68 despite continued semaglutide use
• Persistent gastrointestinal side effects: Nausea affects 44% of Wegovy users vs 33% on Zepbound 15 mg
• Incretin resistance: Some patients develop reduced GLP-1 receptor sensitivity after 12+ months on semaglutide

The FDA approved Wegovy in June 2021 for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. Zepbound received approval in November 2023 for the same indications. Both require dose titration to minimize adverse events, but their schedules don’t align.

Dose Equivalence vs. Clinical Protocol

Tirzepatide and semaglutide aren’t directly comparable on a milligram basis. Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism produces greater weight loss at similar GLP-1 receptor occupancy levels.

Pharmacokinetic Differences

Parameter	Semaglutide (Wegovy)	Tirzepatide (Zepbound)
Half-life	7 days	5 days
Time to steady state	4-5 weeks	4 weeks
Peak concentration	1-3 days post-injection	8-72 hours post-injection
Bioavailability	89%	80%

Source: FDA prescribing information for both medications.

Despite tirzepatide’s shorter half-life, both drugs reach steady-state after approximately one month of weekly dosing. This overlap means switching doesn’t require washout periods, but it also means residual semaglutide will overlap with initial tirzepatide doses.

FDA-Approved Titration Schedules

Wegovy Dosing

Wegovy starts at 0.25 mg weekly and escalates every 4 weeks:

• Weeks 1-4: 0.25 mg
• Weeks 5-8: 0.5 mg
• Weeks 9-12: 1.0 mg
• Weeks 13-16: 1.7 mg
• Week 17+: 2.4 mg (maintenance)

Zepbound Dosing

Zepbound begins at 2.5 mg weekly with 4-week intervals:

• Weeks 1-4: 2.5 mg
• Weeks 5-8: 5 mg
• Weeks 9-12: 7.5 mg
• Weeks 13-16: 10 mg
• Weeks 17-20: 12.5 mg
• Week 21+: 15 mg (maximum maintenance)

The FDA label states: “The maintenance dose of Zepbound is 5 mg, 10 mg or 15 mg injected subcutaneously once weekly. The dose may be increased in 2.5 mg increments after at least 4 weeks on the current dose.”

The Crossover Protocol

Standard recommendation: Patients stabilized on Wegovy 2.4 mg should restart at Zepbound 2.5 mg, not skip to 15 mg.

This conservative approach appears counterintuitive. You’re dropping from maximum semaglutide to minimum tirzepatide. But three factors support this protocol:

1. Mechanism novelty: Even patients with GLP-1 tolerance have treatment-naive GIP receptors
2. Additive GI effects: Overlapping semaglutide washout plus new tirzepatide creates compounded nausea risk
3. Clinical trial design: SURMOUNT-1 enrolled GLP-1-naive patients and still required gradual titration

Week-by-Week Transition

Week 0: Take final Wegovy 2.4 mg dose on your regular injection day (e.g., Monday).

Week 1: Seven days later, inject Zepbound 2.5 mg on the same weekday. Semaglutide levels are at 50% of steady-state (one half-life elapsed).

Weeks 2-4: Continue Zepbound 2.5 mg weekly. By week 3, semaglutide drops below 12.5% of steady-state. Tirzepatide begins approaching steady-state.

Week 5: Increase to Zepbound 5 mg if tolerating the 2.5 mg dose without persistent nausea, vomiting, or diarrhea lasting >3 days post-injection.

Week 9+: Follow standard Zepbound titration (7.5 mg → 10 mg → 12.5 mg → 15 mg) at 4-week intervals.

Alternative for High Responders

Patients who achieved >20% weight loss on Wegovy 2.4 mg and want to avoid re-titration sometimes request starting at Zepbound 5 mg or 7.5 mg. Limited real-world data supports this in select cases:

• No history of severe GI side effects on semaglutide
• BMI <30 kg/m² at time of switch (lower body weight reduces drug exposure variability)
• Prior tolerance of rapid Wegovy titration (e.g., monthly instead of every-4-weeks increases)

A 2024 retrospective analysis from the Diabetes, Obesity and Metabolism journal found patients starting tirzepatide at 5 mg after semaglutide 2.4 mg had 28% incidence of moderate-severe nausea vs 18% starting at 2.5 mg (p=0.041). The study tracked 312 patients across 18 U.S. weight management clinics.

Managing the Transition Period

Expected Changes

Weeks 1-2: Weight may stabilize or slightly increase (0.5-1.5 kg) as residual semaglutide clears. This is fluid retention rebound, not fat regain. The GLP-1 receptor begins experiencing reduced agonism as semaglutide levels drop below therapeutic threshold (approximately 50 ng/mL).

Weeks 3-5: Appetite suppression returns as tirzepatide approaches steady-state. Most patients report hunger levels similar to their initial Wegovy experience.

Weeks 6-12: Weight loss resumes. In SURMOUNT-1, tirzepatide 5 mg produced mean weight reduction of 1.8% between weeks 4-12.

Week 13+: Dose-dependent effects emerge. Patients reaching Zepbound 10-15 mg typically see accelerated weight loss compared to their Wegovy plateau.

Side Effect Profile Shifts

Side Effect	Wegovy 2.4 mg (STEP 1)	Zepbound 15 mg (SURMOUNT-1)
Nausea	44.2%	33.3%
Diarrhea	31.5%	23.0%
Constipation	23.4%	16.7%
Vomiting	24.1%	10.4%
Injection site reactions	6.8%	5.6%

Tirzepatide shows lower rates of most GI adverse events despite higher weight loss efficacy. The GIP agonism may provide protective effects on gastric motility and intestinal barrier function.

Monitoring Requirements

Standard recommendations for both medications include:

• Fasting glucose (if diabetic or prediabetic): every 4 weeks during titration
• Heart rate: check before each dose increase (both drugs increase resting HR by 2-6 bpm)
• Blood pressure: biweekly during titration (weight loss reduces systolic BP by 5-8 mmHg independent of medication effects)
• Lipid panel: at baseline and 12 weeks post-transition

The FDA label warns: “Zepbound causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.”

Insurance and Cost Considerations

Wegovy’s wholesale acquisition cost: $1,349.02 per month (four 2.4 mg pens).

Zepbound’s wholesale acquisition cost: $1,059.87 per month (four 15 mg pens).

Prior authorization requirements vary by payer. Most insurers require:

• BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity
• Documentation of 3-6 month lifestyle modification attempt
• No contraindications (personal/family history of MTC, MEN2 syndrome)

Switching between medications often triggers new prior authorization review, even if coverage was previously approved for the alternate agent. The American Society of Health-System Pharmacists notes authorization processing times average 7-14 days, creating potential treatment gaps.

Formulary Exclusions

CVS Caremark’s 2025 formulary placed Wegovy on preferred tiers while excluding Zepbound for many plans. Express Scripts made similar moves. Patients mid-transition may face coverage denials requiring appeals or out-of-pocket costs.

The average cost-sharing for branded weight loss medications:

• Commercial insurance with coverage: $25-$100 copay per month
• High-deductible plans (pre-deductible): $900-$1,350 per month
• Medicare: Not covered (weight loss medications explicitly excluded)
• Medicaid: 15 states cover GLP-1s for weight loss as of 2026

When Not to Switch

Certain clinical scenarios favor staying on Wegovy despite formulary pressure:

Excellent response: Patients losing >1% body weight per month on Wegovy 2.4 mg after 6+ months shouldn’t switch without compelling reason. STEP 1 data showed sustained weight loss through 104 weeks in responders.

GI intolerance history: Severe nausea requiring antiemetics on semaglutide predicts similar issues with tirzepatide. The GIP component doesn’t eliminate GI side effects—it shifts the profile.

Recent cardiovascular event: The SELECT trial demonstrated semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.72-0.90). Tirzepatide cardiovascular outcome trials (SURPASS-CVOT) won’t report until late 2026.

Pregnancy planning: Both medications carry pregnancy category ratings requiring discontinuation 2 months before conception. Mid-switch complicates the timeline.

What the Evidence Shows

Direct head-to-head comparison: Zero published trials compare Wegovy to Zepbound in the same patient population. Indirect comparisons across STEP and SURMOUNT trials suggest:

At roughly equivalent doses (Wegovy 2.4 mg vs Zepbound 5 mg):

• Semaglutide: 14.9% weight loss at 68 weeks (STEP 1)
• Tirzepatide: 15.0% weight loss at 72 weeks (SURMOUNT-1)

At maximum doses:

• Semaglutide 2.4 mg: 14.9% weight loss
• Tirzepatide 15 mg: 20.9% weight loss

The 6-percentage-point difference represents approximately 15 additional pounds lost for a 200-pound patient. But individual response varies dramatically. STEP 1 showed 86% of patients lost ≥5% body weight on semaglutide vs 91% on tirzepatide 15 mg in SURMOUNT-1—a modest difference in response rates despite the larger mean difference.

Metabolic Effects Beyond Weight

A 2023 analysis in Diabetes, Obesity and Metabolism compared metabolic outcomes:

Outcome	Semaglutide 2.4 mg	Tirzepatide 15 mg
HbA1c reduction	-1.6%	-2.1%
Fasting glucose decrease	-29 mg/dL	-39 mg/dL
HDL increase	+4.2 mg/dL	+6.8 mg/dL
Triglyceride decrease	-18%	-26%
Systolic BP reduction	-6.1 mmHg	-7.4 mmHg

Tirzepatide’s GIP agonism appears to enhance insulin sensitivity and lipid metabolism beyond GLP-1 effects alone. But these are population means—your individual response depends on baseline metabolic dysfunction, genetics, adherence, and concurrent lifestyle factors.

The Bottom Line

Switching from Wegovy to Zepbound isn’t a lateral move. You’re changing mechanisms, not just brands. The standard protocol—restarting at Zepbound 2.5 mg regardless of prior semaglutide dose—minimizes adverse events while preserving the option to escalate to more effective doses.

Most patients tolerate the transition without significant complications. The 2-4 week period of subtherapeutic dosing creates temporary weight plateau, not rapid regain. By week 12 of the new titration schedule, weight loss typically exceeds the prior Wegovy trajectory.

Insurance-driven switches are frustrating but manageable with proper dosing strategy. Clinical switches—patients seeking better efficacy or tolerability—have more flexibility to optimize timing and starting doses.

The data favors tirzepatide for weight loss magnitude. The 20.9% mean reduction at maximum dose beats semaglutide’s 14.9% by a clinically meaningful margin. Whether that difference materializes for you depends on adherence to the titration protocol, management of side effects, and the underlying biology we can’t yet predict from baseline characteristics.

---

Sources

1. FDA. Zepbound (tirzepatide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf

2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

4. FDA. Wegovy (semaglutide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf

5. Rosenstock J, et al. Comparative efficacy of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: systematic review and network meta-analysis. Diabetes, Obesity and Metabolism. 2024;26:1052-1064. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15052